GleamWall
中文EN

ELAB PMGC Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—

Returns

ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.53M$1.31M$681,994$304,136$285,948———
Cost of revenue$1.93M$920,919$451,520$196,852$207,918———
Gross profit$601,444$385,691$230,474$107,284$78,030———
R&D expense$130,261$310,219$47,061$32,902$15,000$66,675$5,832-$164,132
SG&A expense$1.90M$1.61M$1.38M$983,247$726,543$319,839$209,031-$1.00M
Operating income————-$2.20M———
Interest expense$488,385$582,241$474,170$229,753$17,401$2$10,474$32,522
Net income-$2.41M-$2.94M-$4.97M-$2.98M-$2.59M-$562,355-$1.61M-$1.93M
EBITDA————-$2.16M———
EPS (diluted)————————
Balance sheet
Cash & equivalents$113.40M$18.14M$14.35M$5.40M$7.70M$5.68M$5.36M$3.98M
Short-term investments$548,029$650,598$733,405$572,054$804,070$624,838$557,375—
Receivables$1.23M$421,859$428,106$245,423$271,492——$5,276
Inventory$930,234$932,508$253,558$95,098$128,469———
Current assets$16.56M$20.83M$16.39M$6.87M$9.77M$7.30M$6.82M$6.05M
PP&E, net$2.20M$1.90M$1.75M$885,520$413,446——$1,087
Goodwill$3.04M$3.04M$1.86M$977,774$959,535———
Intangibles$5.73M$5.99M$3.80M$2.89M$2.55M$2.07M$2.07M$2.80M
Total assets$133.10M$36.56M$26.03M$12.87M$14.94M$9.38M$8.89M$8.99M
Current liabilities$13.03M$15.33M$11.30M$3.94M$5.46M$326,301$760,268$1.80M
Total liabilities$21.03M$19.83M$13.43M$5.03M$6.45M$326,301$760,268$2.33M
Shareholders' equity$12.11M$16.74M$12.61M$7.84M$8.49M$9.05M$8.13M$6.66M
Shares outstanding889,5866.15M1.94M8,070744,1211.48M707,0765,226
Cash flow statement
Operating cash flow-$2.26M-$1.99M-$2.98M-$1.75M-$1.49M-$1.35M-$1.35M-$2.00M
Capital expenditure$361,426-$27,569$363,087$346,661———$0
Free cash flow-$2.62M-$1.96M-$3.34M-$2.10M———-$2.00M
Investing cash flow-$757,337-$3.68M-$2.48M-$548,642-$2.20M$196,840-$215,319-$439,084
Financing cash flow$98.28M$9.46M$14.41M-$1$5.71M$1.47M$2.94M-$1
Depreciation & amortization$284,805$281,237$159,444$59,756$35,284$20$1,085$134
Stock-based compensation$355,363$174,545$8,216$10,657$13,179$15,842-$58,838$39,646

Free plan shows the latest 8 periods; Pro shows all 17 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.